Clinical trial · Interventional
Study of XL999 in Patients With Metastatic Colorectal Cancer
A Phase 2 Study of XL999 Administered Intravenously to Subjects With Metastatic Colorectal Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Study was terminated due to cardiac toxicities in the subjects
Summary
Brief summary (as posted)
This clinical study is being conducted at multiple sites to determine the activity, safety, and tolerability of XL999 when given weekly to patients with metastatic colorectal cancer (CRC). XL999 is a small molecule inhibitor of multiple kinases including VEGFR, PDGFR, FGFR, FLT-3, and Src, which are involved in tumor cell growth, formation of new blood vessels (angiogenesis), and metastasis.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| XL999 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Response rate
- timeFrame
- Inclusion until disease progression
- measure
- Safety and tolerability
- timeFrame
- Inclusion until 30 days post last treatment
Secondary outcomes (4)
- measure
- Progression-free survival
- timeFrame
- Inclusion until disease progression
- measure
- Duration of response
- timeFrame
- Inclusion until disease progression
- measure
- Overall survival
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Males and females with histologically confirmed metastatic colorectal cancer * Measurable disease according to Response Criteria for Solid Tumors (RECIST) * At least 1 prior therapeutic regimen (chemotherapy or biologic) * ECOG performance status of 0 or 1 * Life expectancy ≥3 months * Adequate organ and marrow function * No other malignancies within 5 years * Signed informed consent Exclusion Criteria: * Radiation to ≥25% of bone marrow within 30 days of XL999 treatment * Treatment with systemic anticancer therapy within 30 days of XL999 treatment * Subject has not recovered to ≤ grade 1 or to within 10% of baseline from adverse events due to other medications administered \>30 days prior to study enrollment * History of or known brain metastases, current spinal cord compression, or carcinomatous meningitis * Uncontrolled and/or intercurrent illness * Pregnant or breastfeeding females * Known HIV
References
Publications (0)
Data not yet available